整理 | GLP1减重宝典内容团队 近日，博瑞生物医药（苏州）股份有限公司公告称，其全资子公司博瑞制药近日获国家药品监督管理局签发《药物临床试验批准通知 书》，BGM1812注射液获准在超重或肥胖人群中开展临床研究。相关临床试验即将启动。 BGM1812注射液是博瑞制药优化设计的长效新型Amylin类似物，兼具良好的分子活性和制剂稳定性。Amylin（胰淀素）是一种由37 个氨基酸构成的饱腹感多肽激素，由胰腺β细胞与胰岛素同步分泌入血。其通过激活中枢饱腹通路抑制食欲，并延缓胃排空、抑制胰高 血糖素分泌，从多环节发挥减重作用。 截至公告披露日，BGM1812注射液减重适应症在美国已获得FDA药物临床试验许可并完成首例受试者入组。目前，全球尚无同靶点制 剂在减重适应症上获批上市。 版权声明：所有「GLP1减重宝典」的原创文章，转载须联系授权，并在文首/文末注明来源、作者、微信ID，否则减重宝典将向其追究法律责 任。部分文章推送时未能与原作者或公众号平台取得联系。若涉及版权问题，敬请原作者联系我们。合作事宜，请添加微信：andyxu365 ▂▂▂▂▂ 每医健旗下减重降糖新媒体矩阵 计划 GLP-1 音程 IAF 减 ...

Group 1 - The core viewpoint of the news is that the company BoRui Pharmaceutical is advancing its weight loss drug candidates BGM0504 and BGM1812, with IND applications submitted in both the US and China, and BGM0504's Phase I clinical trial approved by the FDA [1] - BGM0504 tablet for weight loss has received IND approval in the US and China, with the first dose group about to start administration [1] - BGM1812 injection for weight loss has also submitted IND applications in both countries, while the oral tablet is in preclinical research [1] Group 2 - The company is developing multiple formulations based on GLP-1/GIP dual targets and mylin-like molecules to meet the needs of different weight loss populations [1] - BGM0504 injection has completed US bridging clinical trials and is preparing for Phase III trials, with domestic collaboration with China Resources Sanjiu for R&D and commercialization [1] - The oral formulation of BGM1812 aims for efficient transmembrane delivery and rapid absorption, with advantages pending clinical pharmacokinetic data verification [1] Group 3 - BGM2101 combines BGM0504 with weekly insulin for diabetes treatment, while BGM2102 is a dual-drug combination exploring significant weight loss or low-dose safety, currently in preclinical stages [1] - The company is focusing on new targets such as Myostatin and MC4R, planning to develop long-acting formulations in conjunction with GLP-1 drugs [1] - The oral technology platform is collaborating with Aoli Bio to optimize multi-stage delivery efficiency for the development of BGM0504 and BGM1812 oral tablets [1]

Group 1 - Xinda Biologics reported a total product revenue exceeding 5.2 billion yuan in the first half of 2025, achieving a strong growth of over 35% year-on-year, driven by both oncology and comprehensive pipeline [1] - Eli Lilly's orforglipron demonstrated significant weight loss results in the ATTAIN-1 clinical trial, with the highest dose group (36 mg) achieving an average weight reduction of 12.4 kg, enhancing market confidence in the company's weight loss portfolio [1] Group 2 - AstraZeneca's Fasenra received approval for a new indication in China for the maintenance treatment of severe eosinophilic asthma in children aged 6 to <12 years, further solidifying its market position in respiratory diseases [2] Group 3 - Gan & Lee Pharmaceuticals reported a 57.18% increase in revenue to 2.067 billion yuan and a 101.96% increase in net profit to 604 million yuan in the first half of 2025, indicating strong business growth and enhanced profitability [3] Group 4 - Buchang Pharma announced an exclusive supply agreement with GOODFELLOW in the Philippines for the new biological drug Efparepoetin alfa, marking a significant step in the company's internationalization strategy and enhancing its brand value [4]